Company Filing History:
Years Active: 2016
Title: Karl Anders Hogner: Innovator in Mineralocorticoid Receptor Modulation
Introduction
Karl Anders Hogner is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate mineralocorticoid receptors. His work aims to address oxidative stress in the endothelium, thereby improving vascular function.
Latest Patents
Hogner holds a patent for "Benzoxazinone amides as mineralocorticoid receptor modulators." This patent discloses certain derivatives of benzoxazinone amides, or pharmaceutically acceptable salts thereof, that act as mineralocorticoid receptor modulators. These compounds may reduce oxidative stress in the endothelium and improve vascular function. The patent also covers methods for their potential therapeutic use, pharmaceutical compositions containing them, and processes for preparing such compounds. He has 1 patent to his name.
Career Highlights
Karl Anders Hogner is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on innovative solutions in drug development, particularly in the area of cardiovascular health. His research has the potential to lead to significant advancements in therapeutic options for patients.
Collaborations
Hogner has collaborated with notable colleagues, including Gavin O'Mahony and Michael Kossenjans. These collaborations have contributed to the advancement of research in the field of mineralocorticoid receptor modulation.
Conclusion
Karl Anders Hogner is a prominent inventor whose work in mineralocorticoid receptor modulation holds promise for improving vascular health. His contributions to the pharmaceutical industry are noteworthy and continue to influence the development of innovative therapeutic solutions.